GeneType Multi-Risk Test now includes Melanoma, Pancreatic Cancer & Atrial Fibrillation
March 27, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, March 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and...
Back-to-back Studies Validate geneType Breast Cancer Risk Test
March 13, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and...
New Publication Highlights geneType’s Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification
February 09, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and...
Genetic Technologies Announces Closing of $5 Million Registered Direct Offering
February 07, 2023 10:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven...
Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer
February 06, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and...
Genetic Technologies Announces $5 Million Registered Direct Offering
February 03, 2023 08:35 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven...
GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer
February 03, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and...
GTG to form Strategic Alliance with global testing leader QIAGEN
February 01, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health,...
Quarterly Business Update – December 2022; Sixth Consecutive Quarter of Growth
January 30, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,” Company”, “GTG”), a global leader in guidance-driven genomics-based tests in health,...
Genetic Technologies Presented Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk at ASCOGI Cancer Symposium
January 24, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and...